Aurinia Pharmaceuticals (AUPH) said Tuesday that an experimental medicine for dry-eye syndrome proved to be more effective but slightly less tolerable than Restasis, the best-selling treatment marketed by Allergan.

The Aurinia dry-eye drug is called VOS, and the reported clinical trial results were basically the opposite of what the company expected. Technically, the VOS study failed on tolerability — the primary goal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hi Adam….big fan of yours….high school education from Greece….restaurant business…..I try to understand things but it is hard especially in biotech….just a simple question….are you still kinda positive on aurinia….?…it is fine if you do not answer to this question for any reason….I know how busy you are…..god bless.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy